Nuklearmedizin 2025; 64(02): 177-179
DOI: 10.1055/a-2511-6595
Case Report

Pancreatic Neuroendocrine Tumor incidentally found on 68Ga-PSMA PET/CT

Neuroendokriner Tumor der Bauchspeicheldrüse, zufällig im 68Ga-PSMA-PET/CT entdeckt
Rodrigo Luna
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Daniel A. Laheru
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Eun Ji Shin
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Chen Lossos
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Mahalia T. Robinson
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Steven P. Rowe
2   University of North Carolina, chapel hill, United States
,
Elie Saad
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
,
Mark C. Markowski
1   The Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins Medical Institutions, Baltimore, USA
› Author Affiliations

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PCa) epithelial cells as well as the tumor neovascularity many other neoplasms. We present a case of a 67-year-old man with biochemically recurrent PCa who underwent 68Ga-PSMA-11 PET/CT, which demonstrated an intensely radiotracer-avid pancreatic neuroendocrine tumor. This case demonstrates the equivocal nature of pancreatic lesions, and reinforces the need for further work-up of unusual patterns of uptake, on PSMA-targeted PET/CT. The differential diagnosis of a radiotracer-avid pancreatic lesion should include primary malignancies, among them adenocarcinoma and neuroendocrine tumors.



Publication History

Received: 09 December 2024

Accepted: 27 December 2024

Article published online:
17 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 
  • References

  • 1 de Galiza Barbosa F, Queiroz MA, Nunes RF. et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 2020; 20 (01) 23
  • 2 Salas Fragomeni RA, Amir T, Sheikhbahaei S. et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med 2018; 59 (06) 871-877
  • 3 Rowe SP, Pienta KJ, Pomper MG. et al. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. Eur Urol 2018; 73 (04) 485-487
  • 4 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019; 5 (06) 856-863
  • 5 Sirtl S, Todica A, Ilhan H. et al. Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer. Diagnostics (Basel) 2021; 11 (01) 129
  • 6 Luong TV, Iversen P, Bouchelouche K. et al. 68Ga-Prostate-Specific Membrane Antigen Uptake in a Pancreatic Neuroendocrine Tumor. Clin Nucl Med 2020; 45 (05) 379-382
  • 7 Reyes DK, Demehri S, Werner RA. et al. PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 2019; 23: 72-74